Navigation Links
Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger

MIAMI and VERNON HILLS, Ill., Sept. 26 /PRNewswire-FirstCall/ -- Winston Laboratories, Inc., a company engaged in the discovery and development of products for pain management, and Getting Ready Corporation, a publicly-traded company with no active operations (OTC: GTRY), completed a merger on September 25, 2008, pursuant to a merger agreement providing for the merger of Winston with and into Winston Acquisition Corp., a wholly-owned subsidiary of GTRY. Winston will continue as the surviving entity in the merger and as a wholly-owned subsidiary of GTRY. In connection with the consummation of the merger, GTRY expects to change its name from "Getting Ready Corporation" to "Winston Pharmaceuticals, Inc." GTRY's trading symbol is "GTRY.OB," which the company expects to change in connection with the name change. GTRY intends to apply to have its shares listed on the American Stock Exchange.

(Logo: )

As previously reported, simultaneously with the signing of the merger agreement, on November 13, 2007, a group of investors led by Dr. Phillip Frost, Chairman and Chief Executive Officer of Opko Health, Inc., invested approximately $5.0 million in Winston in exchange for shares of preferred stock and warrants of Winston. Prior to the closing of the merger, a group of investors led by Dr. Phillip Frost and Glenn L. Halpryn made an additional $4.0 million investment in Winston's preferred stock. The proceeds from the investments have and will fund ongoing research and development activities and current operations.

Under the terms of the merger agreement, at the closing of the merger, each common share of Winston issued and outstanding was converted into and exchanged for the right to receive approximately 17.65 shares of common stock of GTRY, and each share of preferred stock of Winston was converted into and exchanged for the right to receive approximately .01751 shares of preferred stock of GTRY, each such share being convertible into 1,000 shares of GTRY common stock. Each Winston option was assumed by GTRY and is now exercisable for approximately 17.65 shares of common stock of GTRY, and each Winston warrant was assumed by GTRY and is now exercisable for approximately .01751 shares of preferred stock of GTRY, each such share being convertible into 1,000 shares of GTRY common stock. As a result of the merger, GTRY's stockholders own approximately 2.56% of the combined company on a fully diluted basis, the stockholders and option holders of Winston, excluding the new investors, own approximately 63.00% of the combined company on a fully diluted basis, the new investors own convertible preferred stock representing approximately 24.44% of the combined company on a fully diluted basis. Warrants issued to certain of the new investors are now exercisable for four years for up to 10% of the common equity of the combined company on a fully diluted basis.

The Board of Directors of GTRY initially will consist of four directors to be appointed by Winston and three directors to be appointed by GTRY. Dr. Joel Bernstein, currently the Chief Executive Officer and principal shareholder of Winston, will serve as Chief Executive Officer of the combined company and as its Chairman of the Board. The company is now headquartered in Vernon Hills, Illinois.

"Dr. Phillip Frost and I are pleased to be working together to build what we expect will become one of North America's leading pharmaceutical companies focused on pain control. We plan to introduce branded pharmaceutical products that will offer new therapeutic options for the growing number of patients suffering from acute or chronic pain," stated Dr. Bernstein.

Glenn Halpryn, the current Chairman and President of Getting Ready Corporation, stated "The management and R&D teams at Winston Laboratories have a successful history of developing pharmaceutical products for pain management. The present merger provides Getting Ready shareholders an opportunity to benefit from the commercial and technical expertise demonstrated by Winston's management, as the Company continues to develop therapeutic products which address unmet medical needs, including the expanding demand for osteoarthritic and surgical pain products."

About Winston Laboratories

Winston Laboratories focuses on major pain indications as well as on niche markets, where there is still significant unmet need for pain management options with improved efficacy, safety, and tolerability profiles. Winston's product candidates span a range of pain indications, including episodic cluster headache, chronic daily headache, osteoarthritis, neuropathic pain, cancer pain and post-operative pain.

Winston Laboratories' flagship compound is civamide, a TRPV-1 (transient receptor potential vanilloid-1) receptor modulator, which we believe provides exceptionally long-lasting analgesic activity. A single oral dose of civamide, for example, provides effective analgesia for at least 7 days in a variety of animal pain models. Winston is engaged in late-stage development of civamide for various pain indications, and submitted its first marketing authorization applications in Europe for relief of osteoarthritis pain during the first quarter of 2008, and will be filing similar marketing authorization applications in Canada and the United States during the fourth quarter of 2008.

About Civamide

Civamide (cis-8-methyl-N-vanillyl-6-nonenamide) is a patented, synthetically produced TRPV-1 receptor modulator, which selectively depresses the activity of the type-C pain fibers. Civamide causes an initial release of the neuropeptides, substance P (SP) and calcitonin-gene related peptide (CGRP). Pain transmission is then diminished by the subsequent depletion of SP and CGRP from the neuron, coupled with suppression of the synthesis and transport of neuropeptides along the neuron.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

SOURCE Getting Ready Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The sea ice is getting thinner
2. Middle East Pharma Manufacturing/Biotech is Ready to Boom
3. Nanotube production leaps from sooty mess in test tube to ready formed chemical microsensors
4. Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
5. Consumer Product Safety Commission not ready for nanotech
6. Chiltern Early Phase: Fully Integrated and Business Ready
7. Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):